Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Susan L. Rosenkranz, Ph.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, Lama JR, Shenje J, De Los Rios J, Comins K, Morganroth J, Diacon AH, Cramer YS, Donahue K, Maartens G. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis. 2021 Feb 12. PMID: 33587897.
    Citations:    Fields:    
  2. Mngqibisa R, Kendall MA, Dooley K, Wu XS, Firnhaber C, Mcilleron H, Robinson J, Cramer Y, Rosenkranz SL, Roa J, Coughlin K, Mawlana S, Badal-Faesen S, Schnabel D, Omoz-Oarhe A, Samaneka W, Godfrey C, Cohn SE. Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. Clin Infect Dis. 2020 07 27; 71(3):517-524. PMID: 31504342.
    Citations:    Fields:    Translation:HumansCells
  3. Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, Diacon AH. Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis. Am J Respir Crit Care Med. 2020 06 15; 201(12):1579-1580. PMID: 32130866.
    Citations:    Fields:    Translation:Humans
  4. Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, Schrank J, Bleasdale SC, Schultz S, Barron M, Stapleton A, Wray D, Chambers H, Fowler VG, Holland TL. The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clin Infect Dis. 2020 04 10; 70(8):1536-1545. PMID: 31157370.
    Citations: 10     Fields:    Translation:HumansCells
  5. Haas DW, Cramer YS, Godfrey C, Rosenkranz SL, Aweeka F, Berzins B, Coombs R, Coughlin K, Moran LE, Gingrich D, Zorrilla CD, Baker P, Cohn SE, Scarsi KK. Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives. Pharmacogenet Genomics. 2020 04; 30(3):45-53. PMID: 32106141.
    Citations: 1     Fields:    Translation:Humans
  6. Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, Diacon AH. Early Bactericidal Activity of Different Isoniazid Doses for Drug Resistant TB (INHindsight): A Randomized Open-label Clinical Trial. Am J Respir Crit Care Med. 2020 Jan 16. PMID: 31945300.
    Citations: 7     Fields:    
  7. Venuto CS, Cramer YS, Rosenkranz SL, Sulkowski M, Wyles DL, Cohen DE, Schmidt J, Alston-Smith BL, Morse GD. Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s. Br J Clin Pharmacol. 2020 01; 86(1):132-142. PMID: 31656054.
    Citations: 1     Fields:    
  8. Scarsi KK, Cramer YS, Rosenkranz SL, Aweeka F, Berzins B, Coombs RW, Coughlin K, Moran LE, Zorrilla CD, Akelo V, Aziz M, Friedman RK, Gingrich D, Swaminathan S, Godfrey C, Cohn SE. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study. Lancet HIV. 2019 09; 6(9):e601-e612. PMID: 31498109.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  9. Browne RW, Rosenkranz SL, Wang Y, Taylor CR, DiFrancesco R, Morse GD. Sources of Variability and Accuracy of Performance Assessment in the Clinical Pharmacology Quality Assurance Proficiency Testing Program for Antiretrovirals. Ther Drug Monit. 2019 08; 41(4):452-458. PMID: 30829950.
    Citations:    Fields:    Translation:Humans
  10. Johnson VA, Cramer YS, Rosenkranz SL, Becker S, Klingman KL, Kallungal B, Coakley E, Acosta EP, Calandra G, Saag MS. Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210. AIDS Res Hum Retroviruses. 2019 08; 35(8):691-697. PMID: 31099252.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  11. Wenzler E, Bleasdale SC, Sikka M, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA. Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants. Antimicrob Agents Chemother. 2018 08; 62(8). PMID: 29891606.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  12. Kiser JJ, Lu D, Rosenkranz SL, Morse GD, DiFrancesco R, Sherman KE, Butt AA. Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s. Drugs R D. 2017 Dec; 17(4):557-567. PMID: 28875397.
    Citations: 2     Fields:    Translation:HumansCells
  13. Martirosov DM, Bidell MR, Pai MP, Scheetz MH, Rosenkranz SL, Faragon C, Malik M, Mendes RE, Jones RN, McNutt LA, Lodise TP. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study. BMC Infect Dis. 2017 08 02; 17(1):534. PMID: 28764660.
    Citations: 2     Fields:    Translation:HumansCells
  14. Huvane J, Komarow L, Hill C, Tran TT, Pereira C, Rosenkranz SL, Finnemeyer M, Earley M, Jiang HJ, Wang R, Lok J, Evans SR. Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017 Mar 15; 64(suppl_1):S18-S23. PMID: 28350899.
    Citations: 5     Fields:    Translation:Humans
  15. De Boni RB, Zheng L, Rosenkranz SL, Sun X, Lavenberg J, Cardoso SW, Grinsztejn B, La Rosa A, Pierre S, Severe P, Cohn SE, Collier AC, Gross R. Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals. Drug Alcohol Depend. 2016 Feb 01; 159:174-80. PMID: 26774947.
    Citations: 4     Fields:    Translation:Humans
  16. Andrade A, Guedj J, Rosenkranz SL, Lu D, Mellors J, Kuritzkes DR, Perelson AS, Ribeiro RM. Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). AIDS. 2015 Nov 28; 29(18):2419-26. PMID: 26558541.
    Citations: 9     Fields:    Translation:HumansCells
  17. Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis. 2015 Jun 15; 60(12):1860-3. PMID: 25722197.
    Citations: 9     Fields:    Translation:Humans
  18. Gross R, Zheng L, La Rosa A, Sun X, Rosenkranz SL, Cardoso SW, Ssali F, Camp R, Godfrey C, Cohn SE, Robbins GK, Chisada A, Wallis CL, Reynolds NR, Lu D, Safren SA, Hosey L, Severe P, Collier AC. Partner-Focused Adherence Intervention for Second-line Antiretroviral Therapy: A Multinational Randomized Trial (ACTG A5234). Lancet HIV. 2015 Jan 01; 2(1):e12-e19. PMID: 25664336.
    Citations: 3     Fields:    
  19. Gross R, Zheng L, La Rosa A, Sun X, Rosenkranz SL, Cardoso SW, Ssali F, Camp R, Godfrey C, Cohn SE, Robbins GK, Chisada A, Wallis CL, Reynolds NR, Lu D, Safren SA, Hosey L, Severe P, Collier AC. Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial. Lancet HIV. 2015 01; 2(1):e12-9. PMID: 26424232.
    Citations: 7     Fields:    Translation:Humans
  20. DiFrancesco R, Taylor CR, Rosenkranz SL, Tooley KM, Pande PG, Siminski SM, Jenny RW, Morse GD. Adding value to antiretroviral proficiency testing. Bioanalysis. 2014 Oct; 6(20):2721-32. PMID: 25413704.
    Citations: 7     Fields:    Translation:Humans
  21. Funderburg NT, Andrade A, Chan ES, Rosenkranz SL, Lu D, Clagett B, Pilch-Cooper HA, Rodriguez B, Feinberg J, Daar E, Mellors J, Kuritzkes D, Jacobson JM, Lederman MM. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. PLoS One. 2013; 8(12):e83514. PMID: 24367599.
    Citations: 32     Fields:    Translation:HumansCellsCTClinical Trials
  22. DiFrancesco R, Rosenkranz SL, Taylor CR, Pande PG, Siminski SM, Jenny RW, Morse GD. Clinical pharmacology quality assurance program: models for longitudinal analysis of antiretroviral proficiency testing for international laboratories. Ther Drug Monit. 2013 Oct; 35(5):631-42. PMID: 24052065.
    Citations: 14     Fields:    Translation:Humans
  23. Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis. 2013 Sep; 208(6):884-91. PMID: 23801609.
    Citations: 31     Fields:    Translation:HumansCellsCTClinical Trials
  24. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93. PMID: 23592830.
    Citations: 22     Fields:    Translation:Humans
  25. Zheng L, Rosenkranz SL, Taiwo B, Para MF, Eron JJ, Hughes MD. The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients. AIDS Res Hum Retroviruses. 2013 Apr; 29(4):652-7. PMID: 23228206.
    Citations: 4     Fields:    Translation:HumansCells
  26. DiFrancesco R, Rosenkranz S, Mukherjee AL, Demeter LM, Jiang H, DiCenzo R, Dykes C, Rinehart A, Albrecht M, Morse GD. Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial. Ther Drug Monit. 2010 Aug; 32(4):458-66. PMID: 20592644.
    Citations: 1     Fields:    Translation:HumansCells
  27. Cramer YS, Rosenkranz SL, Hall SD, Szczech LA, Amorosa V, Gupta SK. Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177. . 2010 Aug; 54(4):e7-9. PMID: 20611034.
    Citations: 4     Translation:Cells
  28. Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis. 2010 Jun 01; 201(11):1686-96. PMID: 20420510.
    Citations: 64     Fields:    Translation:HumansCellsCTClinical Trials
  29. Para MF, Schouten J, Rosenkranz SL, Yu S, Weiner D, Tebas P, White CJ, Reeds D, Lertora J, Patterson KB, Daar ES, Cavert W, Brizz B. Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200. . 2010 Apr 01; 53(4):491-5. PMID: 20130470.
    Citations: 2     Translation:HumansCellsCTClinical Trials
  30. Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH, Aberg J, Sanne I, Parsons T, Kashuba A, Rosenkranz SL, Kmack A, Ferguson E, Dehlinger M, Mildvan D. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis. 2010 Apr 01; 50(7):1041-52. PMID: 20192725.
    Citations: 17     Fields:    Translation:HumansCells
  31. Gross R, Tierney C, Andrade A, Lalama C, Rosenkranz S, Eshleman SH, Flanigan T, Santana J, Salomon N, Reisler R, Wiggins I, Hogg E, Flexner C, Mildvan D. Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Arch Intern Med. 2009 Jul 13; 169(13):1224-32. PMID: 19597072.
    Citations: 29     Fields:    Translation:HumansCells
  32. Gupta SK, Rosenkranz SL, Cramer YS, Koletar SL, Szczech LA, Amorosa V, Hall SD. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS. 2008 Oct 01; 22(15):1919-27. PMID: 18784455.
    Citations: 13     Fields:    Translation:HumansCells
  33. Ma Q, Forrest A, Rosenkranz SL, Para MF, Yarasheski KE, Reichman RC, Morse GD. Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos. 2008 Mar; 29(2):91-101. PMID: 18041735.
    Citations: 2     Fields:    Translation:Humans
  34. Bakshi RP, Hamzeh F, Frank I, Eron JJ, Bosch RJ, Rosenkranz SL, Cramer YS, Ussery M, Flexner C. Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients. AIDS Res Hum Retroviruses. 2007 Nov; 23(11):1360-5. PMID: 18184078.
    Citations: 4     Fields:    Translation:HumansCells
  35. Rosenkranz SL, Yarasheski KE, Para MF, Reichman RC, Morse GD. Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis. Metab Syndr Relat Disord. 2007 Jun; 5(2):163-73. PMID: 18007962.
    Citations: 4     Fields:    
  36. Okusanya O, Forrest A, DiFrancesco R, Bilic S, Rosenkranz S, Para MF, Adams E, Yarasheski KE, Reichman RC, Morse GD. Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks. Antimicrob Agents Chemother. 2007 May; 51(5):1822-6. PMID: 17283195.
    Citations: 4     Fields:    Translation:Humans
  37. Aweeka FT, Rosenkranz SL, Segal Y, Coombs RW, Bardeguez A, Thevanayagam L, Lizak P, Aberg J, Watts DH. The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. AIDS. 2006 Sep 11; 20(14):1833-41. PMID: 16954724.
    Citations: 19     Fields:    Translation:HumansCells
  38. DiFrancesco R, Rosenkranz SL, Craft J, Morse GD. Tutorial reduces protocol deviations in multicenter ACTG trials with pharmacology endpoints. HIV Clin Trials. 2006 Jul-Aug; 7(4):203-9. PMID: 17065032.
    Citations: 3     Fields:    Translation:Humans
  39. Wu H, Huang Y, Acosta EP, Park JG, Yu S, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JG. Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J Pharmacokinet Pharmacodyn. 2006 Aug; 33(4):399-419. PMID: 16583266.
    Citations: 10     Fields:    Translation:HumansCells
  40. Aberg JA, Rosenkranz SL, Fichtenbaum CJ, Alston BL, Brobst SW, Segal Y, Gerber JG. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS. 2006 Mar 21; 20(5):725-9. PMID: 16514303.
    Citations: 10     Fields:    Translation:Humans
  41. Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Remmel RP, Salomon N, Hafner R, Peloquin CA. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis. 2005 Dec 01; 41(11):1638-47. PMID: 16267738.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  42. Morse GD, Rosenkranz S, Para MF, Segal Y, Difrancesco R, Adams E, Brizz B, Yarasheski KE, Reichman RC. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. Antimicrob Agents Chemother. 2005 Aug; 49(8):3373-81. PMID: 16048950.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  43. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, Brobst SW, Segal Y, Aberg JA. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. . 2005 Jul 01; 39(3):307-12. PMID: 15980690.
    Citations: 51     Translation:HumansCTClinical Trials
  44. Wu H, Huang Y, Acosta EP, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JG. Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. . 2005 Jul 01; 39(3):272-83. PMID: 15980686.
    Citations: 25     Translation:HumansCells
  45. Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Peloquin CA, Remmel RP, Chirgwin K, Salomon N, Hafner R. The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis. Clin Infect Dis. 2004 Feb 15; 38(4):556-64. PMID: 14765350.
    Citations: 4     Fields:    Translation:Humans
  46. Huang Y, Rosenkranz SL, Wu H. Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math Biosci. 2003 Aug; 184(2):165-86. PMID: 12832146.
    Citations: 19     Fields:    Translation:HumansCells
  47. Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA, Blaschke TF. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clin Pharmacol Ther. 2003 May; 73(5):406-16. PMID: 12732841.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  48. Pfister M, Labbé L, Hammer SM, Mellors J, Bennett KK, Rosenkranz S, Sheiner LB. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother. 2003 Jan; 47(1):130-7. PMID: 12499180.
    Citations: 48     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  49. Lu JF, Blaschke TF, Flexner C, Rosenkranz SL, Sheiner LB. Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration. Drug Metab Dispos. 2002 Dec; 30(12):1455-61. PMID: 12433819.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  50. Pfister M, Labbé L, Lu JF, Hammer SM, Mellors J, Bennett KK, Rosenkranz S, Sheiner LB. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin Pharmacol Ther. 2002 Aug; 72(2):133-41. PMID: 12189360.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  51. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002 Mar 08; 16(4):569-77. PMID: 11873000.
    Citations: 75     Fields:    Translation:HumansCTClinical Trials
  52. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D, Gulick R, Hughes V, Flexner C, Aweeka F, Hsu A, Gal J. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. . 2001 Jun 01; 27(2):153-60. PMID: 11404537.
    Citations: 22     Translation:HumansCellsCTClinical Trials
  53. Rosenkranz S, Ikuno Y, Leong FL, Klinghoffer RA, Miyake S, Band H, Kazlauskas A. Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression. J Biol Chem. 2000 Mar 31; 275(13):9620-7. PMID: 10734113.
    Citations: 18     Fields:    Translation:AnimalsCells
  54. Krupat E, Rosenkranz SL, Yeager CM, Barnard K, Putnam SM, Inui TS. The practice orientations of physicians and patients: the effect of doctor-patient congruence on satisfaction. Patient Educ Couns. 2000 Jan; 39(1):49-59. PMID: 11013547.
    Citations: 99     Fields:    Translation:Humans
  55. Rosenkranz S, DeMali KA, Gelderloos JA, Bazenet C, Kazlauskas A. Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis. J Biol Chem. 1999 Oct 01; 274(40):28335-43. PMID: 10497192.
    Citations: 26     Fields:    Translation:AnimalsCells
  56. Rosenkranz S, Böhm M, Kazlauskas A. [Pathophysiologic significance of growth factors and new therapeutic concepts in cardiovascular disease]. Med Klin (Munich). 1999 Sep 15; 94(9):496-504. PMID: 10544612.
    Citations:    Fields:    Translation:HumansCells
  57. Rosenkranz S, Kazlauskas A. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors. 1999; 16(3):201-16. PMID: 10372961.
    Citations: 38     Fields:    Translation:HumansAnimalsCells
  58. Gelderloos JA, Rosenkranz S, Bazenet C, Kazlauskas A. A role for Src in signal relay by the platelet-derived growth factor alpha receptor. J Biol Chem. 1998 Mar 06; 273(10):5908-15. PMID: 9488729.
    Citations: 22     Fields:    Translation:AnimalsCells
  59. Rosenkranz SL, Luft HS. Expenditure models for prospective risk adjustment: choosing the measure appropriate for the problem. Med Care Res Rev. 1997 Jun; 54(2):123-43; discussion 144-9. PMID: 9437162.
    Citations: 2     Fields:    Translation:Humans
  60. Dresser MV, Feingold L, Rosenkranz SL, Coltin KL. Clinical quality measurement. Comparing chart review and automated methodologies. Med Care. 1997 Jun; 35(6):539-52. PMID: 9191700.
    Citations: 12     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu).
Rosenkranz's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (272)
Co-Authors (9)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.